Pyxis Oncology, Inc. announced that its President and CEO, Dr. Lara S. Sullivan, will participate in investor conferences, specifically the RBC Capital Markets Global Healthcare Conference on May 21 ...
Pyxis Oncology, Inc. announced that its Compensation Committee has granted stock options for a total of 246,238 shares of its common stock to four newly hired employees, under the 2022 Inducement Plan ...
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results